Drug tested at UVA cleared as 1st COVID-19 treatment
“We are immensely grateful to the patients who participated in this important clinical trial and their families,” said Patrick Jackson, MD, the trial’s principal investigator at UVA. Tested at UVA Health and 67 other sites around the world, remdesivir helped patients with advanced cases of COVID-19 recover 31% faster than patients who received a placebo, according to preliminary trial results released by the National Institutes of Health.
drug
WhsvRelated Articles
If You Invested $1,000 in Gilead Sciences' IPO, This Is How Much Money You'd Have Now
Gilead Sciences priced its shares at $15 before its IPO. Still, though, a $10,000 investment in Gilead's IPO would now be worth nearly $1.8 million. Vistide was the beginning of a long and successful road for Gilead in treating HIV-related conditions. Gilead is also evaluating drugs that could potentially cure HIV in early stage clinical studies.
ipo drug gileads
Google
Experiments going on for a coronavirus vaccine
An experimental coronavirus treatment that was halted a week ago due to "overwhelming" demand is once again available to doctors under an expanded access program. On Saturday, Gilead Sciences CEO Daniel O’Day announced in an open letter that his company was once again making remdesivir available outside of the six ongoing clinical trials investigating whether it is effective as a treatment for COVID-19
drug treatment week
Google